Road map for fibrolamellar carcinoma: Progress and goals of a diversified approach Review


Authors: Kastenhuber, E. R.; Craig, J.; Ramsey, J.; Sullivan, K. M.; Sage, J.; de Oliveira, S.; Riehle, K. J.; Scott, J. D.; Gordan, J. D.; Bardeesy, N.; Abou-Alfa, G. K.
Review Title: Road map for fibrolamellar carcinoma: Progress and goals of a diversified approach
Abstract: Fibrolamellar carcinoma is a rare liver cancer, which primarily afflicts adolescents and young adults worldwide and is frequently lethal. Given the rarity of this disease, patient recruitment for clinical trials remains a challenge. In November 2017, the Second Fibrolamellar Cancer Foundation Scientific Summit (Stamford, CT, USA) provided an opportunity for investigators to discuss recent advances in the characterization of the disease and its surrounding liver and immune context. The Fibrolamellar Cancer Foundation has thus set out a road map to identify and test therapeutic targets in the most efficient possible manner.
Keywords: adolescent; young adult; oncogene; liver; liver cancer; tumor; therapy; resistance; fusion; hepatocellular-carcinoma; breast-cancer cells; fibrolamellar carcinoma; protein-kinase-a; heat; catalytic subunit; dnajb1-prkaca; cyclic amp-dependent protein kinase catalytic subunit; shock protein 40; binding-capacity
Journal Title: Journal of Hepatocellular Carcinoma
Volume: 6
ISSN: 2253-5969
Publisher: Dove Medical Press Ltd  
Date Published: 2019-01-01
Start Page: 41
End Page: 48
Language: English
ACCESSION: WOS:000459482100002
DOI: 10.2147/jhc.S194764
PROVIDER: wos
PMCID: PMC6362920
PUBMED: 30951568
Notes: Article -- Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Ghassan Abou-Alfa
    501 Abou-Alfa